{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-059392","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2026-05-12T20:10:53+00:00","discovered_at":"2026-05-12T20:12:00.537372+00:00","generated_at":"2026-05-12T20:58:25.001846+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rezolute Q3 FY2026 net loss $16.2M, cash $120.3M; Phase 3 sunRIZE shows >50% hypoglycemia reduction","bullets":["Net loss $16.2M vs $18.9M YoY; R&D expense $11.4M, down from $15.3M.","Cash and investments $120.3M at Mar 31, 2026, down from $167.9M at Jun 30, 2025.","Phase 3 sunRIZE: ersodetug reduced time in hypoglycemia by >50% (FAS) and 60-80% (PPS) vs placebo.","FDA Type B meeting in March 2026 acknowledged congenital HI challenges; Rezolute to submit comprehensive datasets.","Tumor HI Phase 3 upLIFT trial enrolling; topline results expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-059392","json":"https://secwatch.observer/filing/0001104659-26-059392.json","markdown":"https://secwatch.observer/filing/0001104659-26-059392.md","text":"https://secwatch.observer/filing/0001104659-26-059392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465926059392/0001104659-26-059392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465926059392/tm2614169d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T20:58:25.001846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d56cc790a5a0cb78f27a3e280698c8ddcfe60692","claim":"Rezolute, Inc. reported for the three months ended March 31, 2026 results: net income $16.2 million.","evidence_excerpt":"Net loss was $16.2 million for the third quarter of fiscal 2026 compared with a net loss of $18.9 million for the same period a year ago.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509261/000110465926059392/0001104659-26-059392-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the three months ended March 31, 2026"},{"label":"Net income","value":"$16.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}